查看文章

The Coronavirus Disease 2019 (COVID-19) continues to be a major source of morbidity and mortality across the globe. Current medical therapy against COVID-19 includes drugs that work by inhibiting viral entry into the cell, inhibiting SARS-CoV2 RNA, inhibiting viral proteases, inhibiting host factors crucial for infection, and immunomodulators [1]. However, most of these therapies are limited by their high cost and parenteral administration that needs to be performed in an in-hospital setting by trained medical staff to avoid adverse effects [1, 2]. Thus, there is an urgent need for effective oral agents, especially in non-hospitalized patients. Molnupiravir, an oral RdRp inhibitor exhibiting advantageous pharmacokinetics, has recently attracted attention due to its ability to inhibit viral replication, reduce viral load rapidly and cause fast recovery [3]. Several trials of molnupiravir have been in COVID-19 patients but may have …